Worth a second look: pharmacovigilance data support current concerns for JAK inhibitors

被引：0

|

作者：

Vallejo-Yague, Enriqueta ^{[1
]}

Weiler, Stefan ^{[1
,2
]}

Burden, Andrea M. ^{[1
]}

机构：

[1] Swiss Fed Inst Technol, Zurich, Switzerland

[2] Associated Inst Univ Zurich, Natl Poisons Informat Ctr, Tox Info Suisse, Zurich, Switzerland

来源：

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2020年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

4252

引用

收藏

页码：472 / 472

页数：1

相关论文

共 4 条

[1] JAK inhibitors in myeloproliferative neoplasms: Rationale, current data and perspective
Tefferi, A.
Pardanani, A.
BLOOD REVIEWS, 2011, 25 (05) : 229 - 237
[2] Fractures and JAK-inhibitors: Evidence of a Safety Signal from the WHO Global Pharmacovigilance VigiBase Data
Clausen, Andreas
Martinez-De la Torre, Adrian
Burden, Andrea
Weiler, Stefan
JOURNAL OF BONE AND MINERAL RESEARCH, 2023, 38 : 18 - 18
[3] Australian data do not support current Pharmaceutical Benefits Scheme criteria for use of tumour necrosis factor-α inhibitors in ankylosing spondylitis
Schachna, L.
Brown, M. A.
INTERNAL MEDICINE JOURNAL, 2006, 36 (11) : 755 - 756
[4] Use of third-generation hepatitis C virus (HCV) enzyme immunoassay (EIA) to resolve second-generation HCV EIA-reactive and second-generation recombinant immunoblot assay-indeterminate blood samples: data to support current Food and Drug Administration guidance on HCV lookback
Busch, MP
Tobler, LH
Tegtmeier, G
Polito, A
Quan, S
Hirschler, NV
Dockter, J
Giachetti, C
Mimms, L
TRANSFUSION, 2000, 40 (01) : 10 - 14